Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow JOHNSON & JOHNSON

Get SEC filing alerts via email and in your feed for JOHNSON & JOHNSON

JNJ

JOHNSON & JOHNSON

About JOHNSON & JOHNSON

Johnson & Johnson is a global healthcare company focused on human health and well-being. It develops, manufactures, and sells pharmaceuticals, medical devices, and consumer health products across various segments including Innovative Medicine and MedTech. Serving markets worldwide, it offers key products in immunology, oncology, cardiology, orthopedics, and vision, leveraging innovation, strong intellectual property, and a broad distribution network to maintain a competitive edge.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from JOHNSON & JOHNSON

1
1
JOHNSON & JOHNSON Johnson & Johnson Reports $24.1 Billion Revenue in Fiscal First Quarter, 9.9% Increase

Via official filing (AI summary) | about 2 months ago | 0 comments

2
1
JOHNSON & JOHNSON Johnson & Johnson Reports 6% Sales Increase to $94.2 Billion in Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
JOHNSON & JOHNSON Johnson & Johnson Reports 6.8% Sales Growth to $24.0 Billion in Fiscal Third Quarter

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
JOHNSON & JOHNSON Johnson & Johnson Reports 5.8% Revenue Growth to $23.7 Billion in Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
JOHNSON & JOHNSON Johnson & Johnson Reports $21.9 Billion Revenue and $11.0 Billion Net Earnings in Fiscal Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
JOHNSON & JOHNSON Johnson & Johnson Reports $88.8 Billion Revenue for Fiscal Year 2024, Up 4.3%

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
JOHNSON & JOHNSON Johnson & Johnson Reports 5.2% Sales Growth, Net Earnings Decline in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments